Trastuzumab treatment of invasive breast ductal carcinoma induces severe edema: a case report.

ABSTRACT:

Background

Trastuzumab, a monoclonal antibody which binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), is the first biological drug approved for the treatment of HER2-positive breast cancer. However, trastuzumab exhibits a series of clinical adverse effects, including cardiac toxicity, nerve damage, abnormal liver function, thrombocytopenia, etc.

Case description

We report a case of a 46-year-old female patient with invasive breast ductal carcinoma (classified as Stage 2B) who developed a rare severe edema in neck, face, chest, abdomen and both upper limbs after a single dose trastuzumab treatment. The patient (~60 kg weight) was administered with trastuzumab (420 mg) with an infusion time of 2 hours. The most severe edema symptom was obser

SUBMITTER: Zhao H 

PROVIDER: S-EPMC9745366 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature